In Q1, Grifols reported a decline in both sales and profitability, and this was largely due to the weakness in the Bioscience division which suffered from reduced plasma collection. However, the group is expected to witness a sizeable recovery from H2 21 onwards, benefiting from the rising plasma collection capacity and COVID-19 vaccination programmes gathering pace. But, caution is warranted, as this recovery largely hinges on improving pandemic situation. The rising threat from the FcRN-based ....
05 May 2021
After a soft Q1, focus shifts to potential recovery in H2 21
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
After a soft Q1, focus shifts to potential recovery in H2 21
- Published:
05 May 2021 -
Author:
Amandeep Goyal -
Pages:
4
In Q1, Grifols reported a decline in both sales and profitability, and this was largely due to the weakness in the Bioscience division which suffered from reduced plasma collection. However, the group is expected to witness a sizeable recovery from H2 21 onwards, benefiting from the rising plasma collection capacity and COVID-19 vaccination programmes gathering pace. But, caution is warranted, as this recovery largely hinges on improving pandemic situation. The rising threat from the FcRN-based ....